Clinical Trial Update: A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550) [Phase 1]

View source ↗

Summary

Phase 1 study in healthy volunteers comparing the absorption of three different oral tablet versions of tasocitinib (CP-690,550) to assess relative bioavailabil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED